Nevro, Globus
Zacks.com on MSN1d
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback